|
KMID : 0614620100560010033
|
|
Korean Journal of Gastroenterology
2010 Volume.56 No. 1 p.33 ~ p.38
|
|
|
24 Weeks Treatment with Pegylated Interferon Alfa Plus Ribavirin May Be Possible in Genotype 1 Chronic Hepatitis C Patients with Rapid Virological Response Who Have Low Pretreatment Viremia
|
|
Moon Sung-Soo
Kang Hyoun-Gu
Seo Jeong-Ah
Jung Eun-Uk
Lee Sang-Heon
Park Sung-Jae
Lee Youn-Jae
Seol Sang-Young
|
|
|
Abstract
|
|
|
Background/Aims: The standard treatment for chronic hepatitis C infected with hepatitis C virus (HCV) genotype 1 is a combination of pegylated interferon alfa and ribavirin over a 48 weeks period. It is unclear if 24 weeks treatment is possible for patients showing a rapid virological response (RVR) without compromising the sustained virological response (SVR) in Korea.
Methods: Between June 2005 and September 2008, among patients chronically infected with the HCV genotype 1 who were treated with pegylated interferon alfa subcutaneously once weekly plus ribavirin based on body weight, 55 patients who had low pretreatment viral load (<600,000 IU/mL) and RVR were enrolled. A total of 55 patients were divided into 24 weeks treatment group (n=29) and the standard treatment group (n=26). The HCV RNA was quantitatively assessed before treatment, and after 12 weeks of treatment, and also qualitatively assessed after 4 weeks of treatment, at end of treatment (24 weeks), and 24 weeks after end of treatment. RVR was defined as undetectable HCV RNA at the 4 weeks of treatment.
Results: Among the 55 patients, SVR was achieved in 100% (29/29) of the patients in 24 weeks treatment and 96.2% (25/26) of the patients in the standard treatment (p=0.473).
Conclusions: HCV genotype 1 infected patients with a low baseline HCV RNA concentration who become HCV RNA negative at week 4 may be treated for 24 weeks without compromising sustained virlolgical response. However, an additional trial will be needed to optimize the treatment duration.
|
|
|
KEYWORD
|
|
|
Hepatitis C, Short term treatment, Rapid virological response, Pegylated interferon, Ribavirin
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|